Overall, ESMO 2025 reinforced the growing potential of biomarkers in cancer, with AI integration accelerating adoption. As ...

Novartis’ Itvisma (onasemnogene) has been approved by the US FDA to treat spinal muscular atrophy (SMA) in children aged two ...

As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector ...

Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research ...

Regeneron Pharmaceuticals’ Libtayo (cemiplimab) has received approval from the European Commission for the adjuvant treatment ...

Over the past six decades, anti-thrombotic drug therapies have undergone a revolution, leading to major improvements in ...

SQD, an innovative recruitment and retention success scoring tool that helps clinical trial sponsors predict, measure, and ...

Tonix Pharmaceuticals has launched Tonmya (cyclobenzaprine), a newly approved oral treatment for adults with fibromyalgia.

Can you believe there are still outdated myths about the strategic value Medical Affairs (MA) brings to the table? There’s ...

Markets and regulators will keep shifting, but an agile medical affairs function, built on flexible resourcing and ...

Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences.

Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led ...